Cell penetrating peptide conjugates of steric block oligonucleotides.

Authors:
Lebleu B; Moulton HM; Abes R; Ivanova GD; Abes S and 4 more

Journal:
Adv Drug Deliv Rev

Publication Year: 2007

DOI:
10.1016/j.addr.2007.09.002

PMCID:
PMC7103303

PMID:
18037527

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Adv Drug Deliv Rev

Abbreviation: Adv Drug Deliv Rev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Drug Therapy

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics.
Kang DD; Li H; Dong Y. (2023) - Transparency Score: 3/6
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery.
Han G; Noh D; Lee H and 4 more (2023) - Transparency Score: 3/6
Imaging drug delivery to the lungs: Methods and applications in oncology.
Man F; Tang J; Swedrowska M and 2 more (2022) - Transparency Score: 3/6
In vivo fate and intracellular trafficking of vaccine delivery systems.
Lee J; Kim D; Byun J and 3 more (2022) - Transparency Score: 3/6
Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.
Aldarondo D; Wayne E. (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"We thank Philippe Clair and Martin Fabani for their helpful discussions, Paul Prevot for assistance with fluorescence microscopy, Donna Williams and David Owen with synthesis of PNA and peptides, and the Chemistry department of AVI Biopharma for synthesis of PMO and peptides. This work was funded by a grant from EC framework 5 (contract QLK3-CT-2002-01989 to BL and MG) and from IFCPAR (contract 3205-A to BL). S. Abes and R. Abes are recipients of pre-doctoral fellowships from Ligue contre le Cancer and Région Languedoc-Roussillon."

Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025